Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) traded at a new 52-week high today of $4.25. So far today approximately 1.6 million shares have been exchanged, as compared to an average 30-day volume of 626,000 shares.
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology and oncology-focused biopharmaceutical company. It is engaged in developing treatments to transform the lives of patients. The company has a clinical portfolio comprised of a first in class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and a small molecule inhibitor targeting oncology.
ASLAN Pharmaceuticals Limited has overhead space with shares priced $3.79, or 15.7% below the average consensus analyst price target of $4.50.
ASLAN Pharmaceuticals Limited share prices have moved between a 52-week high of $4.25 and a 52-week low of $0.83 and are now trading 357% above that low price at $3.79 per share.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer